A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV ...
allAfrica.com on MSN2d
Africa: A Jab That Could Protect Against HIV for a Year At a Time, and Other Highlights From Major ConferenceA single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV ...
Yearly lenacapavir injection for HIV prevention shows safety and long-lasting effects, according to clinical trial results.
Gilead Sciences hits a 52-week high buoyed by investor optimism. We believe there is still room for growth and recommend the ...
As Gilead Sciences prepares to launch twice-yearly lenacapavir pre-exposure prophylaxis (PrEP) later this year, the company is also developing once-yearly formulations that could make an even greater ...
Zacks.com on MSN4d
Buy 3 U.S. Giants Flying High Year to Date Defying Severe VolatilityU.S. stock markets have been enduring severe volatility over the past month. Wall Street’s recent turmoil is broad-based. The ...
The CDC budget cuts could pose headwinds for HIV drugmakers like Gilead and Merck but are unlikely to severely cripple their ...
Gilead Sciences shares dropped more than 3% Wednesday following a Wall Street Journal report that the Health and Human ...
So, assuming 2% growth, Gilead is slightly undervalued. In fact, Gilead appears valued for 0% growth. Actually, this may be a ...
JPMorgan says that while the Wall Street Journal’s report on potential Centers for Disease Control and Prevention funding cuts for HIV ...
An H5N1 infection can be fatal for domestic animals, but there are steps you can take to minimize the risk of them catching ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback